Status:
UNKNOWN
Oncologist-Initiated Cancer Genetic Testing for Pancreatic Cancer Patients
Lead Sponsor:
Sunnybrook Health Sciences Centre
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pancreatic cancer (PC) has a dismal prognosis. Approximately 10% of PC patients carry a germline pathogenic variant in a cancer susceptibility gene, whose identification can lead to better treatments ...
Eligibility Criteria
Inclusion
- • Newly diagnosed exocrine pancreatic cancer
- Patient consents to blood draw and genetic testing
- Treating oncologist at Odette Cancer Centre
- No conditions that would prevent patients from completing the study-related questionnaires or understanding the consent process
- Valid phone number
- Email address to send link to online family history questionnaire
- Treating physician agrees to complete the referrals
Exclusion
- Patient declines genetic testing
- Blood transfusion within the past month
- Allogenic bone marrow transplantation
- History of comprehensive panel genetic testing
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04316507
Start Date
April 1 2020
End Date
March 31 2021
Last Update
October 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada, M4n 3M5